Kardiocentrum and Cardiovascular Research Centre, University Hospital Motol, V Úvalu 84, Prague, Czech Republic.
Europace. 2012 Apr;14(4):509-14. doi: 10.1093/europace/eur327. Epub 2011 Oct 11.
To evaluate the results of permanent epicardial pacing in children.
All consecutive patients from one country (n = 119, period 1977-2009) undergoing permanent epicardial pacemaker implantation at <18 years of age (median 1.8 years, inter-quartile range 0.3-6.4 years) were studied retrospectively. Median patient follow up was 6.4 years (inter-quartile range 2.9-11.1 years); 207 generators, 89 atrial and 153 ventricular pacing leads were implanted. The probability of absence of any pacing system dysfunction was 70.1 and 47.2% at 5 and 10 years after implantation, respectively. Overall probability of continued epicardial pacing was 92.8 and 76.1% at 5 and 10 years, respectively, and increased in the recent implantation era (post-2000, P = 0.04). The use of steroid-eluting leads decreased the risk of exit block with a hazard ratio (HR) of 0.20 [95% confidence interval (CI) 0.09-0.44, P < 0.001)]. The use of bipolar Medtronic 4968 leads reduced the risk of surgical reintervention because of fracture, insulation break, outgrowth or exit block in comparison to the unipolar 4965 lead design (HR 0.12, 95% CI 0.04-0.40, P < 0.001). The AutoCapture™ feature (HR 0.08, 95% CI 0.02-0.36, P < 0.001) and steroid-eluting leads (HR 0.30, 95% CI 0.11-0.84, P = 0.021) decreased the risk of battery depletion.
The probability of continued epicardial pacing in children was 76% at 10 years after implantation, increased for implantation in recent years, and allowed transvenous pacing to be deferred to a significantly greater age. The use of bipolar steroid-eluting leads and of a beat-to-beat capture tracking feature significantly increased pacing system longevity and decreased the need for surgical reinterventions.
评估儿童永久性心脏外膜起搏的结果。
回顾性研究了来自一个国家(n=119,1977-2009 年期间)的所有连续患者,这些患者在<18 岁时接受了永久性心脏外膜起搏器植入(中位数 1.8 岁,四分位距 0.3-6.4 岁)。中位患者随访时间为 6.4 年(四分位距 2.9-11.1 年);植入了 207 个发生器、89 个心房和 153 个心室起搏导线。植入后 5 年和 10 年无任何起搏系统功能障碍的概率分别为 70.1%和 47.2%。整体上,植入后 5 年和 10 年继续进行心脏外膜起搏的概率分别为 92.8%和 76.1%,并且在最近的植入时代(2000 年后,P=0.04)有所增加。与非类固醇洗脱导线相比,使用类固醇洗脱导线可将出口阻滞的风险降低 20%(危险比[HR]为 0.20[95%置信区间(CI)0.09-0.44],P<0.001)。与单极 4965 导线设计相比,使用双极 Medtronic 4968 导线可降低因骨折、绝缘破裂、生长或出口阻滞而进行手术再次干预的风险(HR 0.12,95%CI 0.04-0.40,P<0.001)。AutoCapture™功能(HR 0.08,95%CI 0.02-0.36,P<0.001)和类固醇洗脱导线(HR 0.30,95%CI 0.11-0.84,P=0.021)降低了电池耗竭的风险。
儿童心脏外膜起搏的概率在植入后 10 年时为 76%,近年来植入的比例有所增加,并且能够将经静脉起搏延迟到年龄更大。使用双极类固醇洗脱导线和逐搏捕获跟踪功能可显著延长起搏系统的使用寿命,并减少手术再次干预的需要。